BGPT: Best Evidence: HDACi BRAF/MEK and HDACi PD-1 Evidence Quality ( preclinical vs clinical )

Explore by Goal

Quick Analysis Plan Copied

The supplied evidence does not test the HDACi+BRAF/MEK or HDACi+PD-1 hypotheses: it contains only strong preclinical BRAF/MEK mechanism studies and HDACi monotherapy phase 1/2 trials, with zero HDACi-combination clinical data supplied.

Long Analysis Plan

What the supplied evidence actually shows

The evidence package is mismatched to the query. No record tests HDAC inhibitors combined with BRAF/MEK inhibitors or with PD-1 blockade. What exists splits into two unrelated tiers: (1) high-quality preclinical BRAF/MEK mechanism work, and (2) HDACi monotherapy phase 1/2 safety trials across non-oncology-indication contexts (HIV reservoir, ITP, myelofibrosis, sarcoma) .

The strongest records are structural/biochemical: an asymmetric BRAF dimer crystal-structure study (scored 9/10 quality) and an in vitro BRAF activation/reconstitution assay with cryo-EM at 3.8 Å . MEK-inhibitor pharmacology shows context-dependent potency (GDC-0973 BRAF V600E EC50 0.005 µM vs KRAS G13D 0.52 µM) . Combination-adjacent preclinical data exist only for MEK+AKT (ZIP synergy up to 23.2 in ES-2) and BRAF+MEK in murine melanoma . Neither involves HDACi.

The critical gap

Zero supplied records quantify HDACi synergy with MAPK inhibition or checkpoint blockade in cells, animals, or patients. The eight ClinicalTrials.gov records are all completed phase 1/2 HDACi-based trials, none with a BRAF/MEK or PD-1 combination arm . Any claim that HDACi+BRAF/MEK or HDACi+PD-1 is "best evidence" cannot be supported or refuted from these sources; the preclinical-vs-clinical comparison the query requests is structurally impossible here.

What would change this conclusion: randomized or at least phase 2 data for an HDACi (e.g., panobinostat, chidamide, romidepsin) combined with BRAF/MEK inhibitors in melanoma, or with anti-PD-1 in any solid tumor — none is present. Confidence in the verdict above is high precisely because it is a negative result about evidence coverage, not about the biology.

Feedback:

Updated: October 28, 2026

Top Data Sources Export MCP

1. This study presents the first X-ray crystal structures of a BRAF:MEK1 tetramer featuring NtA motif–mediated asymmetric BRAF dimers, showing that this asymmetric dimer is a catalytically active state essential for BRAF activation and detailing how MEK1 phosphorylation and cellular signaling proceed within the RAF–MEK–ERK pathway. [2025]

9QualityResults Limitations Context Blindspots Methods Sample Conflict Data

↗ Paper Review ↗ Full Paper

2. This study elucidates the distinct mechanisms of MEK inhibition that determine the efficacy of MEK inhibitors in KRAS versus BRAF-driven cancers, highlighting the importance of specific interactions with MEK for optimal therapeutic outcomes. [2013]

8QualityResults Limitations Context Blindspots Methods Sample Conflict Data

↗ Paper Review ↗ Full Paper

3. The study develops an in vitro BRAF activation assay using autoinhibited BRAF:14-3-3:MEK complexes to show that active-state KRAS, especially with phosphatidylserine-containing membranes, promotes disassembly of autoinhibition and triggers BRAF dimerization/activation, with SMP-mediated pS365 dephosphorylation and RBD:KRAS interactions (and their disruption) shaping the activation process, providing a platform for drug discovery targeting BRAF regulation. [2025]

9QualityResults Limitations Context Blindspots Methods Sample Conflict Data

↗ Paper Review ↗ Full Paper

4. The study reveals that BRAF fusion oncogenicity (notably KIAA1549::BRAF in pediatric gliomas) depends on the fusion partner for membrane localization and maturation via the POMT1/2-driven O-mannosylation, and that inhibiting POMT1/2 or disrupting secretory-pathway maturation reverses transformation, highlighting a MAPK-independent therapeutic vulnerability in BRAF fusions. [2025]

10QualityResults Limitations Context Blindspots Methods Sample Conflict

↗ Paper Review ↗ Full Paper

5. This study investigates the combined effects of BRAF and MEK inhibitors on murine melanoma, demonstrating that their synchronous administration can enhance tumor control while reducing skin toxicity associated with MEK inhibitors. [2013]

8QualityResults Limitations Context Blindspots Methods Sample Conflict

↗ Paper Review ↗ Full Paper

Key Insight

The evidence package contains a category error: strong BRAF/MEK mechanistic preclinical data plus unrelated HDACi monotherapy trials create a false impression of combination-therapy support; absence of any HDACi combination arm is the decisive finding.

Keep Exploring

Which HDAC isoform selectivity profile (class I vs IIb) maximizes predicted synergy with MEK inhibition based on the resistance pathways observed in trametinib-resistant LGSOC cells?

Does the avutometinib-stabilized autoinhibited BRAF state (EMD-70053) alter chromatin-state dependencies such that HDACi sensitivity differs between MAPK-pathway-inhibited versus untreated cells?

What baseline tumor immune-contexture biomarkers would most efficiently enrich for responders in a first-in-human HDACi plus anti-PD-1 combination trial?

Hypothesis Graveyard

'The clinical HDACi trials listed support combination strategies' — falsified: all eight supplied trials are monotherapy or non-MAPK/non-PD-1 backbones.

'Structural BRAF studies translate directly to combination therapy logic' — overstated: authors themselves flag overexpression artifacts, truncated constructs, and absent cancer models.

Potential Experiments

Cross-reference the supplied CRISPR kinome hits (PDPK1, PI3K-Akt kinases) with HDACi sensitivity data in DepMap to predict which LGSOC/NSCLC contexts would respond to triple HDACi+MEK+AKT inhibition before any animal work.

Test whether avutometinib-stabilized autoinhibited BRAF (PDB 902Z state) is hypersensitive to HDACi-driven transcriptional changes by measuring pERK recovery kinetics ± panobinostat in the ES-2 line with 4.5 nM trametinib sensitivity.

Science Art

Science Movie

Make a narrated HD Science movie for this answer ($32 per minute)

Discussion

BGPT Bias

My synthesis inherits the supplied record set's imbalance toward BRAF/MEK preclinical work, and I may overweight structural elegance as a proxy for translational relevance.

Stay current without chasing every paper.

Know what changed, what holds up, and what remains uncertain. Every Friday. No ads.

The Evidence Layer for Scientific AI

Ask questions across claims linked to experiments, exact results, limitations, and sources.Know what the science actually supports before you trust the answer.

Explore by Goal

Quick Analysis Plan Copied

Long Analysis Plan

What the supplied evidence actually shows

The critical gap

Top Data Sources Export MCP

2. This study elucidates the distinct mechanisms of MEK inhibition that determine the efficacy of MEK inhibitors in KRAS versus BRAF-driven cancers, highlighting the importance of specific interactions with MEK for optimal therapeutic outcomes. [2013]

5. This study investigates the combined effects of BRAF and MEK inhibitors on murine melanoma, demonstrating that their synchronous administration can enhance tumor control while reducing skin toxicity associated with MEK inhibitors. [2013]

12. A comprehensive review of the PD-1/PD-L1 immune checkpoint pathway in the tumor immune microenvironment of non-small cell lung cancer (NSCLC) and the clinical development, efficacy, safety, biomarkers, and combination strategies of PD-1/PD-L1 inhibitors in NSCLC. [2015]

Ask a Follow-Up

Key Insight

The evidence package contains a category error: strong BRAF/MEK mechanistic preclinical data plus unrelated HDACi monotherapy trials create a false impression of combination-therapy support; absence of any HDACi combination arm is the decisive finding.

Keep Exploring

Which HDAC isoform selectivity profile (class I vs IIb) maximizes predicted synergy with MEK inhibition based on the resistance pathways observed in trametinib-resistant LGSOC cells?

Does the avutometinib-stabilized autoinhibited BRAF state (EMD-70053) alter chromatin-state dependencies such that HDACi sensitivity differs between MAPK-pathway-inhibited versus untreated cells?

What baseline tumor immune-contexture biomarkers would most efficiently enrich for responders in a first-in-human HDACi plus anti-PD-1 combination trial?

Hypothesis Graveyard

'The clinical HDACi trials listed support combination strategies' — falsified: all eight supplied trials are monotherapy or non-MAPK/non-PD-1 backbones.

'Structural BRAF studies translate directly to combination therapy logic' — overstated: authors themselves flag overexpression artifacts, truncated constructs, and absent cancer models.

Potential Experiments

Cross-reference the supplied CRISPR kinome hits (PDPK1, PI3K-Akt kinases) with HDACi sensitivity data in DepMap to predict which LGSOC/NSCLC contexts would respond to triple HDACi+MEK+AKT inhibition before any animal work.

Test whether avutometinib-stabilized autoinhibited BRAF (PDB 902Z state) is hypersensitive to HDACi-driven transcriptional changes by measuring pERK recovery kinetics ± panobinostat in the ES-2 line with 4.5 nM trametinib sensitivity.

Science Art

Science Movie

Make a narrated HD Science movie for this answer ($32 per minute)

Discussion

BGPT Bias

My synthesis inherits the supplied record set's imbalance toward BRAF/MEK preclinical work, and I may overweight structural elegance as a proxy for translational relevance.

Stay current without chasing every paper.

My BGPT

Trending

The Evidence Layer for Scientific AI

Ask questions across claims linked to experiments, exact results, limitations, and sources.Know what the science actually supports before you trust the answer.

Explore by Goal

Quick Analysis Plan Copied

Long Analysis Plan

What the supplied evidence actually shows

The critical gap

Top Data Sources ExportMCP

2. This study elucidates the distinct mechanisms of MEK inhibition that determine the efficacy of MEK inhibitors in KRAS versus BRAF-driven cancers, highlighting the importance of specific interactions with MEK for optimal therapeutic outcomes. [2013]

5. This study investigates the combined effects of BRAF and MEK inhibitors on murine melanoma, demonstrating that their synchronous administration can enhance tumor control while reducing skin toxicity associated with MEK inhibitors. [2013]

12. A comprehensive review of the PD-1/PD-L1 immune checkpoint pathway in the tumor immune microenvironment of non-small cell lung cancer (NSCLC) and the clinical development, efficacy, safety, biomarkers, and combination strategies of PD-1/PD-L1 inhibitors in NSCLC. [2015]

Ask a Follow-Up

Key Insight

The evidence package contains a category error: strong BRAF/MEK mechanistic preclinical data plus unrelated HDACi monotherapy trials create a false impression of combination-therapy support; absence of any HDACi combination arm is the decisive finding.

Keep Exploring

Which HDAC isoform selectivity profile (class I vs IIb) maximizes predicted synergy with MEK inhibition based on the resistance pathways observed in trametinib-resistant LGSOC cells?

Does the avutometinib-stabilized autoinhibited BRAF state (EMD-70053) alter chromatin-state dependencies such that HDACi sensitivity differs between MAPK-pathway-inhibited versus untreated cells?

What baseline tumor immune-contexture biomarkers would most efficiently enrich for responders in a first-in-human HDACi plus anti-PD-1 combination trial?

Hypothesis Graveyard

'The clinical HDACi trials listed support combination strategies' — falsified: all eight supplied trials are monotherapy or non-MAPK/non-PD-1 backbones.

'Structural BRAF studies translate directly to combination therapy logic' — overstated: authors themselves flag overexpression artifacts, truncated constructs, and absent cancer models.

Potential Experiments

Cross-reference the supplied CRISPR kinome hits (PDPK1, PI3K-Akt kinases) with HDACi sensitivity data in DepMap to predict which LGSOC/NSCLC contexts would respond to triple HDACi+MEK+AKT inhibition before any animal work.

Test whether avutometinib-stabilized autoinhibited BRAF (PDB 902Z state) is hypersensitive to HDACi-driven transcriptional changes by measuring pERK recovery kinetics ± panobinostat in the ES-2 line with 4.5 nM trametinib sensitivity.

Science Art

Science Movie

Make a narrated HD Science movie for this answer ($32 per minute)

Discussion

BGPT Bias

My synthesis inherits the supplied record set's imbalance toward BRAF/MEK preclinical work, and I may overweight structural elegance as a proxy for translational relevance.

Stay current without chasing every paper.

My BGPT

Trending

Top Data Sources Export MCP